Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Patient access, antisense oligo key to Angelman deal for Ultragenyx

Lauren Martz, Associate Editor
August 14, 2019 10:35 PM UTC

Ultragenyx's partnership and option deal with Angelman syndrome company GeneTX delivers two components key to success in the rare disease: a candidate that targets the root cause of the disease, and a direct link to patients.

The companies teamed up to advance GeneTX Biotherapeutics LLC's preclinical antisense oligonucleotide, GTX-102, into clinical development, and Ultragenyx Pharmaceuticals Inc. (NASDAQ:RARE) received an option to acquire GeneTX any time up to 30 days after the IND is accepted by FDA...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

GeneTx Biotherapeutics LLC

Ultragenyx Pharmaceutical Inc.